PDCD1 and cancer: Nowadays, immune checkpoint inhibitors have achieved notable success in a variety of cancers, which potentiate lymphocyte responses by specifically effecting on cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death protein 1 (PD-1) [23].